Koyfin Home > Directory > Health Care > Aimmune Therap > Cash from Financing Activities

Aimmune Therap Cash from Financing Activities Chart (AIMT)

Aimmune Therap annual/quarterly Cash from Financing Activities from 2014 to 2020.
  • Aimmune Therap Cash from Financing Activities for the quarter ending June 06, 2020 was $2m a -51.40% decrease of -1m year over year
  • Aimmune Therap Cash from Financing Activities for the last 12 months ending June 06, 2020 was $302m a 51.68% increase of 156m year over year
  • Aimmune Therap Annual Cash from Financing Activities for 2019 was $56m a -435.38% decrease of -243m from 2018
  • Aimmune Therap Annual Cash from Financing Activities for 2018 was $299m a 97.82% increase of 293m from 2017
  • Aimmune Therap Annual Cash from Financing Activities for 2017 was $7m a -2,167.53% decrease of -141m from 2016
Other Cash Flow Metrics:
  • Aimmune Therap Cash Flow from Operations for the quarter ending September 09, 2018 was $-41m a 22.62% decrease of -9m year over year
  • Aimmune Therap Levered Free Cash Flow (FCF) for the quarter ending September 09, 2018 was $-25m a 30.11% decrease of -7m year over year
View Chart On Koyfin

Quarterly AIMT Cash from Financing Activities Data

06/2020$2m
03/2020$285m
12/2019$11m
09/2019$3m
06/2019$3m
03/2019$39m
12/2018$101m
09/2018$2m
06/2018$4m
03/2018$191m

Annual AIMT Cash from Financing Activities Data

2019$56m
2018$299m
2017$7m
2016$148m
2015$235m
2014$0m
2013$16m